ClinicalTrials.gg
RecruitingNCT06857773PUMP-IT RCTUpdated Mar 4, 2025

Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusion Pump Therapy With Systemic Therapy

A Phase 3 interventional study of Intra arterial infusion Floxuridine (FUDR) combined with systemic therapy and Hepatic arterial infusion pump (HAIP) in Colorectal Neoplasms, Floxuridine and Liver Metastases, sponsored by The Netherlands Cancer Institute. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-04.

Sponsored by The Netherlands Cancer Institute · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
306
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies testing floxuridine in Colorectal Neoplasms — 5 open to participants now, 6 under way, 3 of them phase 3. Floxuridine · Colorectal Neoplasms.

Planned enrollment
4th of 25
306 · median 49
Started
2024
with 1 other
Phase 3
7 of 27
3 open now
Registered
25th of 27
by date
Lead sponsor
2 of 27
The Netherlands Cancer Institute

Among the 27 studies testing floxuridine in Colorectal Neoplasms, this one is the 4th largest by planned enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2024, is one of 7 in phase 3, and was the 25th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

5 of the 27 studies testing floxuridine in Colorectal Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About floxuridine

Floxuridine: first FDA approval 1970 (FUDR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing floxuridine in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The goal of this randomized clinical trial is to investigate induction treatment with Hepatic Arterial Infusion Pump therapy combined with systemic therapy (HAIP-SYST) in chemotherapy-naive patients with unresectable colorectal liver metastases without extrahepatic disease. The main question it aims to answer is if combined HAIP-SYST improves survival compared to induction treatment with systemic therapy alone. Patients in the control arm will receive systemic therapy according to standard of care.

Study procedures experimental arm

  • Surgery for pump placement and resection of the primary tumor
  • Pre- and postoperative imaging (CT-anghiography, 99mTc-MAA scintigraphy)
  • Induction treatment with hepatic arterial infusion pump therapy with Floxuridine combined with systemic therapy

Study procedures both arms

  • Evaluation of resectability status by a National Liver Panel with surgeons and radiologists
  • Questionnaires for Quality of Life
03

Conditions studied

  • Colorectal Neoplasms
  • Floxuridine
  • Liver Metastases
  • Vascular Access Device
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years.
  • confirmed colorectal adenocarcinoma.
  • Unresectable synchronous CRLM according to a National Liver Panel (CT-scan obtained ≤ 4 weeks prior to registration).
  • No extrahepatic . Patients with small (≤ 10 mm) extrahepatic lesions that are not clearly suspicious of metastases are eligible.
  • No previous systemic therapy for colorectal cancer.
  • Positioning of a catheter for HAIP chemotherapy is technically feasible based on imaging. The default site for the catheter insertion is the gastroduodenal artery (GDA). Accessory or aberrant hepatic arteries are no for catheter implantation. The GDA should have at least one branch to the liver. Accessory or aberrant hepatic arteries should be ligated to allow for cross perfusion to the entire liver through intrahepatic shunts. Patients with celiac trunk stenosis are not eligible. Patients with both a replaced right and replaced left hepatic artery are not eligible.
  • performance status 0 or 1.
  • of at least 12 weeks.
  • Known mutation status of RAS and BRAFV600E.
  • Primary tumour in situ and resectable without therapy.
  • Patient is eligible for surgery.
  • Patient is eligible for doublet chemotherapy.
  • Laboratory requirements: i.e. adequate bone marrow, liver and renal function (obtained within 15 days prior to registration).

    • ≥ 5.5 mmol/L
    • (ANC) ≥1.5 x 109/L
    • ≥100 x 109/L
    • total ≤ 1.5 times the (ULN)
    • ASAT/ ≤ 5 x ULN
    • ALAT/ALT ≤ 5 x ULN
    • alkaline phosphatase ≤ 5 x ULN
    • Serum creatinine ≤ 1.5 x upper limit of normal or a (eGFR) ≥ 45 ml/min;
    • or INR \< 1.5 x ULN, unless coumarin derivates are used. All patients using coumarin derivates will be treated with LMWH or DOAC instead.
  • Before registration, written must be given and signed according to ICH/GCP, and national/local regulations.

Exclusion criteria

Exclusion Criteria:

  • Prior hepatic radiation, resection, or ablation.
  • Any , comorbidity or condition that interferes with the planned study treatment or the prognosis of CRLM, determined by the treating physician.
  • History of prior malignancy except for the following: (a) malignancy treated with curative intent and with no evidence of active disease present within 3 years prior to inclusion, (b) curatively treated malignancies felt to be at low risk for recurrence by treating physician and MDT, (c) adequately controlled nonmelanomatous skin cancer, (d) adequately treated carcinoma in situ without current evidence of disease.
  • Obstructive primary tumour requiring emergency surgery, primary tumour necessitating a multivisceral resection/abdominoperineal resection or a rectal tumour requiring preoperative short-course radiotherapy or chemoradiotherapy for local tumour control.
  • MMR deficiency.
  • DPD-deficiency.
  • Pregnant or lactating women.
  • Serious concomitant systemic disorders that would compromise the safety of the patient or his/her ability to complete the study, at the discretion of the investigator.
  • Organ allografts requiring therapy.
  • Serious non-healing wound, ulcer, or bone fracture.
  • Chronic treatment with (dose of ≥ 10 mg/day methylprednisolone equivalent excluding inhaled steroids).
  • Known serious infections (uncontrolled or requiring treatment).
  • History of psychiatric disability judged by the investigator to be , precluding or interfering with compliance for HAIP-SYST or standard systemic therapy.
  • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.
  • Underlying liver disease including liver fibrosis and cirrhosis
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
306 participants (estimated)

Study arms

  • Active comparator
    A: systemic therapy according to standard of care

    Patients included in the control arm will receive systemic therapy according to standard of care

    Drug: Systemic therapy (standard of care)

  • Experimental
    B: combined HAIP-therapy and systemic therapy

    Patients included in the experimental arm undergo surgery for pump placement and resection of the primary tumor. Followed by combined induction treatment with floxuridine via the hepatic arterial infusion pump (1cycle is 4 weeks) and systemic therapy (FOLFOX or FOLFIRI, 1 cycle is 2 weeks)

    Drug: Intra arterial infusion Floxuridine (FUDR) combined with systemic therapy · Device: Hepatic arterial infusion pump (HAIP)

Interventions

  • DrugIntra arterial infusion Floxuridine (FUDR) combined with systemic therapy

    Drug page: FloxuridineStudies of FloxuridineFloxuridine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Floxuridine is administered via the hepatic arterial infusion pump directly to the hepatic artery with a continous flowrate for a period of 2 weeks. Intra arterial infusion of FUDR is combined with systemic therapy (FOLFOX/FOLFIRI) intravenously. Administration of FUDR via the chemopump is every 4 weeks and systemic therapy is administered every 2 weeks.

  • DeviceHepatic arterial infusion pump (HAIP)

    The HAIP (pump) is implanted during surgery combined with resection of the primary tumor before start of induction treatment with Floxuridine and concomitant systemic therapy

  • DrugSystemic therapy (standard of care)

    Patient included in the control arm will receive systemic therapy according to standard clinical practice. Induction therapy regimens include: CAPOX (3 weekly) or FOLFOX/FOLFIRI/FOLFOXIRI (2weekly) with optional addition of Bevacizumab (2 weekly)

06

What researchers measure

Primary outcomes

  1. Overall survival

    Defined as the time between randomization and the event of death.

    Time frame: Up to five years after randomization

Secondary outcomes

  1. Progression-free survival

    Defined as the time between randomization and the first event defined as recurrence or death, whichever comes first.

    Time frame: Up to five years after randomization

  2. Hepatic progression-free survival

    Defined as the time between randomization and the event of progression confined to the liver.

    Time frame: Up to five years after randomization

  3. Conversion to resection rate

    Defined as conversion surgery with intention of complete local treatment of all CRLM

    Time frame: if CRLM convert to resectable, often at 3-6 months after start induction treatment

  4. Complete local treatment rate

    R0/1 resection or ablation of all visible CRLM

    Time frame: if CRLM convert to resectable, often at 3-6 months after start induction treatment

  5. Objective response rate (ORR)

    Defined as complete or partial response according to RECIST 1.1

    Time frame: During protocol treatment, up to 6 months of induction treatment

  6. Disease control rate (DCR)

    Defined as a complete or partial and stable disease

    Time frame: During protocol treatment, up to 6 months of induction treatment

  7. Pathological response rate

    Defined as a major and complete pathological response of resected lesions according to the Mandard score.

    Time frame: Pathological assessment of conversion surgery after induction treatment

  8. Surgical complication rate

    of HAIP placement and/or any tumour related surgery. Defined as the percentage of surgery-related (HAIP placement and/or any protocol tumor related surgery) complications grade ≥3 according to the Clavien-Dindo classification

    Time frame: at 30 days an 90 days postoperatively

  9. Adverse events and toxicity of HAIP-SYST and systemic therapy

    Defined as the percentage of treatment related AEs grade ≥ 3 according to Common Terminology Criteria for Adverse Events (CTCAE), version 5.0

    Time frame: During protocol treatment

  10. Quality of Life (QoL)

    Assessed by standardized Quality of Life questionnaires (EORTC QLQ-C30 \& EQ-5D3L)

    Time frame: Up to five years after randomization

  11. Cost-effectiveness

    Expressed by costs per quality adjusted life years (QALYs) and estimated according to the Health Technology Assessment (HTA) methods. Productivity loss is assessed by adjusted standardized Productivity Costs Questionnaires (iPCQ)

    Time frame: Up to five years after randomization

07

Study locations

1 of 1 sites recruiting
  • Antoni van Leeuwenhoek-Netherland Cancer Institute
    Amsterdam, 1066CX, Netherlands
    Recruiting
    • Elisa M ter Kuile · Contactpump@nki.nl · +3120 512 9111
    • Koert FD Kuhlmann · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Jan 2030, 62 months after the start.

Of 106 non-industry phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 116. This study's planned 62 months is close to that.

Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2024
First posted
Mar 4, 2025
StartActual
Nov 21, 2024
Primary completionEst.
Jan 2030
CompletionEst.
Jan 2035
Last update
Mar 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06857773
Responsible party
Sponsor
First posted
Mar 4, 2025
Start date
Nov 21, 2024
Primary completion
Jan 2030 (estimated)
Completion
Jan 2035 (estimated)
Last update
Mar 4, 2025

Study contacts

Koert FD Kuhlmann, MD PhD
Contact
pump@nki.nl
+31205129111

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Floxuridine

Start the discussion